The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2019 | T-cell bispecific antibody targeting intracellular WT1 in AML
Marion Subklewe, MD, LMU Hospital Munich, Munich, Germany, outlines a study evaluating a 2+1 T-cell bispecific (TCB) antibody immunotherapy for acute myeloid leukemia (AML). The T-cell receptor (TCR)-like TCB targets the intracellular tumor antigen Wilms tumor 1 (WT1) in the context of human leukocyte antigen allele A*02 (HLA-A2). Preclinical data indicates TCR-like TCBs targeting intracellular tumor antigens are a promising tool for cancer immunotherapy. Interestingly, combination of WT1-TCB with lenalidomide further enhanced antibody-mediated T-cell cytotoxicity against primary AML cells. Prof. Subklewe suggests that in a future clinical trial WT1-TCB efficacy can be increased with the addition of lenalidomide. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
